Roberto Salgado, MD, PhD is a pathologist based in Belgium with expertise in breast pathology and immuno-oncology. He is Co-chair of the International Immuno-Oncology Biomarker Working Group.
Over the past several years we have seen large advances and dedication of resources to immuno-oncology. We’ve also seen that information extracted by quantifying Tumor Infiltrating Lymphocytes (TILs) on routine histologic sections adds significant predictive and prognostic information in this area.
We have known for over a hundred years, however that assessment of histologic features adds powerful information correlated with patient outcomes. Are we poised for a renaissance in histologic examination, with digital pathology as the engine?
